CNTB (Connect Biopharma Holdings) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.38
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price